Randomized, double-blind, placebo controlled, phase 2 study of pemetrexed and cisplatin plus enzastaurin versus pemetrexed and cisplatin plus placebo in chemonaive patients with advanced, unresectable, or metastatic (stage IIIB or IV) non-small cell lung cancer
Latest Information Update: 06 Nov 2020
At a glance
- Drugs Enzastaurin (Primary) ; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- Sponsors Eli Lilly and Company
- 09 Oct 2020 Status changed from completed to discontinued.
- 01 Feb 2012 Results published in Oncology.
- 12 Oct 2009 Tolerability results have been presented at the 15th European Cancer Conference and the 34th Congress of the European Society for Medical Oncology.